CCN2 and pancreatic neoplasm: FibroGen has developed a monoclonal anti-CTGF blocking antibody FG-3019, which inhibits tumor growth and metastasis in pancreatic cancer in preclinical studies [26–28], and has been shown to be safe and well-tolerated [29].